Information Provided By:
Fly News Breaks for February 25, 2020
NLS, APA, AMCX, REGN, HPQ
Feb 25, 2020 | 10:14 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. HP Inc. (HPQ) upgraded to Buy from Hold at Loop Capital with analyst Ananda Baruah saying the company's earnings call included a handful of announcements that suggest the stock "continues to move higher from here through various means." 2. Regeneron (REGN) upgraded to Outperform from In Line at Evercore ISI and to Buy from Hold at Jefferies. 3. AMC Networks (AMCX) upgraded to In-Line from Underperform at Imperial Capital with analyst David Miller saying his Underperform thesis has played out with the shares down 27% since his October 29, 2019 downgrade. 4. Apache (APA) upgraded to Overweight from Sector Weight at KeyBanc with analyst Leo Mariani saying he sees a "reasonable likelihood" the company will see continued exploration success in Suriname. 5. Nautilus (NLS) upgraded to Buy from Hold at Lake Street with analyst Christopher Krueger saying the company's Q4 results were better than expected and positive commentary on new product launches provides confidence that 2019 was a "bottom," with improving results expected over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For HPQ;REGN;AMCX;APA;NLS From the Last 2 Days
REGN
Sep 21, 2021 | 06:50 EDT
BMO Capital analyst Matthew Luchini raised the firm's price target on Regeneron (REGN) to $706 from $669 and keeps an Outperform rating on the shares. The company's full EMPOWER-3 data presented at ESMO confirms the survival benefit of Libtayo+chemo over chemo alone, reinforcing previously announced top-line data, the analyst tells investors in a research note. Luchini adds that he continues to see Regeneron's oncology portfolio as "increasingly diversified" with initial co-stim data in 2022, stating that the totality of data points in Libtayo indicate a "competitive profile" relative to Merck's (MRK) Keytruda.